BBD-1

BBD-1 is an experimental therapeutic agent described as a "multi-target immune enhancement targeting agent." It is currently being developed for the treatment of hypersensitivity reaction (IgA) vasculitis, also known as Henoch-Schönlein purpura (HSP), and its associated renal complication, IgA vasculitis nephritis (IgAVN). The agent is designed to modulate the immune system and reduce the inflammatory response that characterizes the disease, which involves the deposition of IgA-containing immune complexes in small blood vessels. Developed by researchers led by Qifeng Zhang at the Henan University of Chinese Medicine, BBD-1 is being evaluated in Phase 2 clinical trials to compare its efficacy and safety against standard glucocorticoid treatments. The goal of the therapy is to provide a more targeted approach to managing symptoms such as skin purpura, joint pain, and abdominal pain while potentially offering a better safety profile than conventional immunosuppressants.

Other names

BBD-1 multi-target immune enhancement targeting agentBBD1 multi-target immune enhancement targeting agentBBD 1 multi-target immune enhancement targeting agent